Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

NCT00908349 is registered in ClinicalTrials.gov with Supernus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00908349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00908349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
Lead sponsor
Supernus Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2009
Completion date
November 30, 2011
Enrollment
214 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

partial epilepsy